Table 1 |
||
|
Patient demographics and clinical characteristics |
||
|
NGX-4010 (n = 102) |
Control (n = 53) |
|
|
|
||
|
Demographics |
||
|
|
||
|
Age (yr), mean ± SD |
68.7 ± 12.00 |
71.2 ± 11.26 |
|
Male, n (%) |
47 (46%) |
25 (47%) |
|
Race |
||
|
White |
89 (87%) |
45 (85%) |
|
Black or African American |
6 (6%) |
3 (6%) |
|
Asian |
1 (1%) |
1 (2%) |
|
American Indian or Alaska Native |
0 (0%) |
1 (2%) |
|
Native Hawaiian or Other Pacific Islander |
0 (0%) |
0 (0%) |
|
Other |
6 (6%) |
3 (6%) |
|
|
||
|
Clinical characteristics |
||
|
|
||
|
Duration of Pain (yr), mean ± SD |
2.7 ± 2.92 |
3.4 ± 4.00 |
|
Baseline a "Average Pain for the Past 24 Hours", mean ± SD |
5.4 ± 1.58 |
5.3 ± 1.53 |
|
On Concomitant Pain Medicationb, n (%) |
78 (76%) |
42 (79%) |
|
Opioids |
26 (25%) |
13 (25%) |
|
Anticonvulsants |
26 (25%) |
18 (34%) |
|
Antidepressants |
10 (10%) |
6 (11%) |
|
Other |
52 (51%) |
30 (57%) |
|
Size of Painful Area at Screening (cm2), mean ± SD |
337.9 ± 226.46 |
334.2 ± 221.92 |
|
|
||
|
Baseline pain level was defined as the mean of all available non-biased Screening NPRS scores in that category. A patient was defined as being on concomitant pain medication if pain medication started prior to day of treatment, continued on the day of treatment, and was taken for at least 7 days. |
||
|
Webster et al. BMC Neurology 2010 10:92 doi:10.1186/1471-2377-10-92 |
||
